Based on artificial intelligence-assisted generation and in-depth in-silico evaluation of potential inhibitors targeting Stearoyl-CoA desaturase 1 (SCD-1)

Description

Qu Wang and four colleagues used artificial intelligence in 2026 to generate candidate drugs against an enzyme that many cancers lean on. The enzyme, SCD-1, converts saturated fats into the supple kind that cell membranes need, and tumours overusing it grow faster, spread more, and resist a form of cell death called ferroptosis. Existing blockers suffer from off-target harm, so the team let a design platform propose fresh molecules.

The platform generated 399 novel compounds, which were then filtered by docking into the enzyme, two-hundred-nanosecond molecular dynamics runs, and binding energy calculations. Four finalists bound stably and tightly, with low drift across the simulations and strong computed affinity. All results are computational, with no cell or animal testing yet. The authors offer the four leads and the AI workflow as a starting kit for tumour-specific SCD-1 drug development.

Catalog record

Source: https://europepmc.org/article/MED/PMC13558694